Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

67 064 0	89 318	
We (the	entity) give ASX the following inform	ation.
	1 - All issues complete the relevant sections (attach sheets if t	there is not enough space).
1	⁺ Class of ⁺ securities issued or to be issued	Performance Share Rights
2	Number of ⁺ securities issued or to be issued (if known) or maximum number which may be issued	937,881
3	Principal terms of the ⁺ securities (e.g. if options, exercise price and expiry date; if partly paid ⁺ securities, the amount outstanding and due dates for payment; if ⁺ convertible securities, the conversion price and dates for conversion)	Performance Share Rights vesting on 31 August 2021 and 31 August 2022, subject to the achievement of performance criteria.

Name of entity

ABN

Ava Risk Group Limited

⁺ See chapter 19 for defined terms.

4	Do the ⁺ securities rank equally in all respects from the ⁺ issue date with an existing ⁺ class of quoted ⁺ securities?	Upon vesting each of the resultant ordinary shares will rank equally with existing ordinary shares on issue.
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	Nil
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	In accordance with the Company's Employee Share Plan for the purpose of incentivising and retaining employees.
6a	Is the entity an ⁺ eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections $6b-6h$ in relation to the *securities the subject of this Appendix 3B, and comply with section $6i$	
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of ⁺ securities issued without security holder approval under rule 7.1	Nil
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A

6e	Number of ⁺ securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of ⁺ securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	8,092,334	
7	⁺ Issue dates	28 October 2019	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.		
			Γ .
		Number	+Class
8	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in section 2 if applicable)	234,115,568	Fully paid ordinary shares

⁺ See chapter 19 for defined terms.

Number	+Class
--------	--------

9	Number and +class of all +securities not quoted on ASX (including the +securities in section	1,500,000	Unlisted Employee Options over Ordinary Shares subject to an exercise price of \$0.23 Expiring 15 March 2020
	2 if applicable)	200,000	Employee Options over Ordinary Shares subject to an exercise price of \$0.21 Expiring 10 November 2020
		125,000	Options issued in accordance with Option Exchange Deed between the Company, Optionholder and Maxsec Group Limited and subject to and exercise price of \$0.10 and expiring 19/05/2020
		250,000	Options issued in accordance with Option Exchange Deed between the Company, Optionholder and Maxsec Group Limited and subject to and exercise price of \$0.10 and expiring 19/05/2020
		2,000,000	Options issued in accordance with Option Exchange Deed between the Company, Optionholder and Maxsec Group Limited and subject to and exercise price of \$0.12 and expiring 31/12/2020
		1,500,000	Unlisted Options over Ordinary Shares subject to an exercise price of \$0.125 per shares and expiring on 31/12/2021
		1,500,000	Unlisted Options over Ordinary Shares subject to an exercise price of \$0.15 per shares and expiring on 31/12/2021
		3,000,000	Unlisted Options over Ordinary Shares subject to an exercise price of \$0.20 per shares and expiring on 31/12/2021
		197,148	Performance Share Rights vesting on 01 July 2020 subject to achievement of vesting hurdles
		197,148	Performance Share Rights vesting on 01 July 2021 subject to achievement of vesting hurdles
		997,497	Performance Share Rights vesting on 31 August 2021 subject to achievement of vesting hurdles.
		997,503	Performance Share Rights vesting on 31 August 2022

⁺ See chapter 19 for defined terms.

			subject to achievement of vesting hurdles.
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	
Part	2 - Pro rata issue		
11	Is security holder approval required?	N/A	
12	Is the issue renounceable or non-renounceable?	N/A	
13	Ratio in which the *securities will be offered	N/A	
14	⁺ Class of ⁺ securities to which the offer relates	N/A	
15	⁺ Record date to determine entitlements	N/A	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A	
17	Policy for deciding entitlements in relation to fractions	N/A	
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/A	
19	Closing date for receipt of acceptances or renunciations	N/A	

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements in full through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Issue date	N/A

⁺ See chapter 19 for defined terms.

Part 3 - Quotation of securitiesYou need only complete this section if you are applying for quotation of securities

34	Type of ⁺ securities (tick one)		
(a)	X	+Securities described in Part 1	
(b)		All other +securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employed inserting above countries when restriction and acquirities inserted a positive or conversion of convertible countries.	

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35	✓	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	✓	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37		A copy of any trust deed for the additional *securities NOT APPLICABLE

Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	
39	⁺ Class of ⁺ securities for which quotation is sought	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	

⁺ See chapter 19 for defined terms.

41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in clause 38)	Number	⁺ Class

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 28 October 2019

(Director/Company secretary)

Print name: Kim Clark

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	211,094,439	
 Add the following: Number of fully paid ⁺ordinary 	Nil	
securities issued in that 12 month period under an exception in rule 7.2		
 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval 		
 Number of partly paid +ordinary securities that became fully paid in that 12 month period 		
Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items		
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	478,872	
"A"	210,615,567	

Step 2: Calculate 15% of "A"		
"B"	0.15 [Note: this value cannot be changed]	
Multiply "A" by 0.15	31,592,335	
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule	
 Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued: Under an exception in rule 7.2 	23,500,001	
 Under rule 7.1A With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	23,500,001	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15 Note: number must be same as shown in Step 2	31,592,335	
Subtract "C" Note: number must be same as shown in Step 3	23,500,001	
Total ["A" x 0.15] – "C"	8,092,334 [Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
Multiply "A" by 0.10	
7.1A that has already been used Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	
"E"	Nil

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	Nil
Note: number must be same as shown in Step 3	
Total ["A" x 0.10] – "E"	Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.